Table 1.
Patient characteristics.
| Characteristic | Fully vaccinated group (Case group) N = 97688 | Unvaccinated group (Control group) N = 42094 | ||
|---|---|---|---|---|
| Immunosuppressed, N = 4283 (4.4%) |
Immunocompetent, N = 93405 (95.6%) |
Immunosuppressed, N = 1253 (3.0%) |
Immunocompetent, N = 40841 (97.0%) |
|
| Age Median (IQR) | 59 (46 – 69) | 52(36 – 65) | 49 (35 – 62) | 39 (28 – 54) |
| Gender No. (%) | ||||
| - Male | 1591 (37.1%) | 39814 (42.6%) | 474 (37.8%) | 17472 (42.8%) |
| - Female | 2692 (63.9%) | 53588 (58.0%) | 779 (62.2%) | 23369 (57.2%) |
| Race No. (%) | ||||
| - Caucasian | 3462 (80.8%) | 72872 (78.0%) | 971 (77.5%) | 29275 (71.7%) |
| - African American | 446 (10.4%) | 6910 (7.4%) | 189 (15.1%) | 5758 (14.1%) |
| - Other/Unknown | 375 (8.8%) | 13623 (14.6%) | 93 (7.4%) | 5808 (14.2%) |
| Vaccine Type No. (%) | ||||
| - BNT162b2 | 2046 (47.8%) | 53178 (56.9%) | N/A | N/A |
| - mRNA-1273 | 2064 (48.2%) | 35256 (37.7%) | N/A | N/A |
| - Ad26.COV2.S | 173 (4.1%) | 4971 (5.4%) | N/A | N/A |
| SARS-CoV-2 infections No. (%) | 119 (2.8%) | 1146 (1.3%) | 85 (6.8%) | 1470 (3.6%) |
| COVID-19 hospitalizations No. (%) | 15 (0.35%) | 45 (0.05%) | 7 (0.56%) | 155 (0.38%) |